Director/PDMR Shareholding

Convatec Group PLC

17 March 2026

 

17 March 2026

Convatec Group Plc
("Convatec" or "the Company")

Director/PDMR Shareholding 

The Company has been notified of the following transactions in relation to Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary shares of 10 pence each in the Company ("Shares").

Vesting of Awards under the Company's Long Term Incentive Plan ("LTIP") and Deferred Bonus Plan ("DBP")

On 15 March 2026, conditional share awards granted to each of Jonny Mason, Chief Executive Officer and Fiona Ryder, Chief Financial Officer in 2023 under the LTIP in the form of Performance Share Awards ("PSA") vested and were released to them on 16 March 2026.

Additionally, on 15 March 2026, awards granted to each of Jonny Mason in 2023 under the DBP in the form of Restricted Stock Units ("RSU") and awards granted to Fiona Ryder in 2023 under the LTIP in the form of RSUs also vested and were released to them on 16 March 2026.

For all awards released to the PDMRs, on 16 March 2026 sufficient shares were sold to satisfy income tax and National Insurance ("NI") liabilities, with the balance of shares retained by the PDMRs, as summarised in the table below:

PDMR	Share Award	Shares vested	Shares sold to satisfy income tax & NI liabilities	Share price	Total shares acquired
Jonny Mason	PSA	511,469	241,114	£2.344	270,355
Jonny Mason	DBP	106,137	50,035	£2.344	56,102
Fiona Ryder	PSA	27,001	12,729	£2.344	14,272
Fiona Ryder	RSU	31,748	14,967	£2.344	16,781

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jonny Mason
2	Reason for the notification
a)	Position/status	Chief Executive Officer and PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Convatec Group Plc
b)	LEI	213800LS272L4FIDOH92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary share of 10p each in Convatec Group Plc
	Identification code	GB00BD3VFW73
b)	Nature of the transaction	a.    Vesting of PSA under the LTIP. b.    Vesting of RSU under the DBP.
c)	Price(s) and volume(s)	Price(s) Volume(s) a. £0 511,469 b. £0 106,137
d)	Aggregated information
	- Aggregated volume	617,606
	- Price	£0
e)	Date of the transaction	2026-03-15
f)	Place of the transaction	Outside a trading venue
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary share of 10p each in Convatec Group Plc
	Identification code	GB00BD3VFW73
b)	Nature of the transaction	a.    Immediate sale of shares awarded under the LTIP to cover tax and national insurance liabilities. b.    Immediate sale of shares awarded under the DBP to cover tax and national insurance liabilities.
c)	Price(s) and volume(s)	Price(s) Volume(s) a. £2.344 241,114 b. £2.344 50,035
d)	Aggregated information
	- Aggregated volume	291,149
	- Price	£2.344
e)	Date of the transaction	2026-03-16
f)	Place of the transaction	XLON

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Fiona Ryder
2	Reason for the notification
a)	Position/status	Chief Financial Officer and PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Convatec Group Plc
b)	LEI	213800LS272L4FIDOH92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary share of 10p each in Convatec Group Plc
	Identification code	GB00BD3VFW73
b)	Nature of the transaction	a.    Vesting of PSA under the LTIP. b.    Vesting of RSU under the LTIP.
c)	Price(s) and volume(s)	Price(s) Volume(s) a. £0 27,001 b. £0 31,748
d)	Aggregated information
	- Aggregated volume	58,749
	- Price	£0
e)	Date of the transaction	2026-03-15
f)	Place of the transaction	Outside a trading venue
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary share of 10p each in Convatec Group Plc
	Identification code	GB00BD3VFW73
b)	Nature of the transaction	a.    Immediate sale of shares awarded under the LTIP to cover tax and national insurance liabilities. b.    Immediate sale of RSUs awarded under the LTIP to cover tax and national insurance liabilities.
c)	Price(s) and volume(s)	Price(s) Volume(s) a. £2.344 12,729 b. £2.344 14,967
d)	Aggregated information
	- Aggregated volume	27,696
	- Price	£2.344
e)	Date of the transaction	2026-03-16
f)	Place of the transaction	XLON

Enquiries

James Kerton, Company Secretary                                                                     
Email: [e-mail]     

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

 

END